Stage IV Laryngeal Squamous Cell Carcinoma AJCC v7 Recruiting Phase 2 Trials for Cabozantinib (DB08875)

IndicationStatusPhase
DBCOND0088881 (Stage IV Laryngeal Squamous Cell Carcinoma AJCC v7)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03468218Pembrolizumab & Cabozantinib in Patients With Head and Neck Squamous Cell Cancer Who Have Failed Platinum Based TherapyTreatment